-+ 0.00%
-+ 0.00%
-+ 0.00%
The drug SRT-003-1, a subsidiary of Fosun Pharmaceuticals (600196.SH), was approved for clinical trials
Share
Listen to the news

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that recently, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd. (“Xing Rui Jingxuan”), the holding subsidiary of the company, received approval from the State Drug Administration for clinical trial approval of [18F] F-SR031 injection (“SRT-003-1”) for the use of positron emission tomography (PET) imaging of fibroblast-activating protein (FAP) positive lesions in patients with solid tumors. Xingrui Jingxuan plans to conduct phase I clinical research on this drug in China when conditions are met.

SRT-003-1 is a radioactive in vivo diagnostic drug targeting fibroblast activating protein (FAP). It is intended mainly for PET imaging of FAP positive lesions in patients with solid tumors. FAP is a type II transmembrane serine protease, which belongs to the prolinyl oligopeptidase family. It is hardly expressed in normal tissues, and is selectively highly expressed in cancer-associated fibroblasts (CAF) of various epithelial tumors such as gastric cancer, esophageal cancer, lung cancer, colorectal cancer, and ovarian cancer. FAP inhibitors labeled with fluorine [18F] can be specifically combined with FAP on the CAF surface, so that tumor lesions with high FAP expression are highly ingested in PET imaging, so they can be used for tumor diagnosis, staging, and efficacy evaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending